Coinvestigator Appendix

Coinvestigator Appendix

Austria S Strasser-Fuchs, MD (Graz, site investigator), T Berger, MD, PhD

(Innsbruck, site investigator), K Vass, MD, PhD (Vienna, site investigator). Belgium C Sindic, MD, PhD

(Brussels, site investigator), B Dubois, MD, PhD (Leuven, site investigator), D Dive, MD, V Delvaux, MD, PhD (Liège, site investigators), J Debruyne, MD, PhD (Ghent, site investigator); Canada L Metz, MD

(Calgary, site investigator), G Rice, MD, M Kremenchutzky, MD (London, site investigators), P Duquette,

MD, Y Lapierre, MD (Montreal, site investigators), M Freedman, MD (Ottawa, steering committee), A

Traboulsee (Vancouver, site investigator), P O'Connor, MD (Toronto, site investigator); CzechRepublic P Stourac, MD (Brno, site investigator), R Talab, MD, M Valis, MD, PhD (Hradec Kralove, siteinvestigators), O Zapletalova, MD (Ostrava, site investigator), I Kovarova, MD, E Medova, MD (Prague,site investigators), J Fiedler MD, PhD (Plzen, site investigator); Denmark J Frederiksen, MD (Glostrup,site investigator); France B Brochet, MD, PhD (Bordeaux, site investigator), T Moreau, MD, PhD (Dijon,site investigator), P Vermersch, MD, PhD (Lille, site investigator), J Pelletier, MD (Marseille, siteinvestigator), G Edan, MD, PhD (Rennes, steering committee), M Clanet, MD, PhD, B David, MD, PhD

(Toulouse, site investigators), P Clavelou, MD, PhD (Clermont Ferrand, site investigator), C Lebrun-

Frenay, MD (Nice, site investigator), O Gout, MD (Paris, site investigator); Finland M Kallela, MD

(Helsinki, site investigator), T Pirttila, MD (Kuopio, site investigator), J Ruutiainen, MD, JP Erälinna, MD

(Turku, site investigators), K Koivisto, MD (Seinajoki, site investigator), M Reunanen, MD, I Keskinarkus,

MD (Oulu, site investigators), I Elovaara, MD (Tampere, site investigator); Germany A Villringer, MD, PhD H Altenkirch, MD (Berlin, site investigators), L Bauer, MD; M Ghazi, MD; C Pohl, MD (Berlin, steeringcommittee), K Wessel, MD (Braunschweig, site investigator), H-P Hartung, MD, PhD (Deusseldorf,steering committee), W Steinke, MD, PhD, B Kieseier, MD (Düsseldorf, site investigators), H Kolmel, MD (Erfurt, site investigator), P Oschmann, MD, M Berghoff, MD (Giessen, site investigators), R Diem, MD, B

Kitze, MD (Göttingen, site investigators), A Dressel, MD (Greifswald, site investigator), F Hoffmann, MD (Halle/Saale, site investigator), K Baum, MD (Hennigsdorf, site investigator), S Jung, MD (Homburg/Saar,site investigator), H Felicitas Petereit, MD, D Reske, MD (Cologne, site investigators), M Sailer, MD (Magdeburg, site investigator), J Kohler, MD (Mainz, site investigator), B Tackenberg, MD (Marburg, siteinvestigator), L Klotz, MD, (Muenster, site investigator) RHohlfeld, MD, T Kuempfel, MD, PhD (Munich,site investigators), K-H Henn, MD (Offenbach, site investigator), A Steinbrecher, MD, K Angstwurm, MD (Regensburg, site investigators), H Tumani, MD, PhD (UIm, site investigator), R Gold, MD, P Rieckmann,

MD, C Kleinschnitz, MD, PhD (Würzburg, site investigators); Hungary R Komoly, MD, PhD, G Gacs, MD,

G Jakab, MD, G Panczel, MD (Budapest, site investigators), T Csepany, MD, PhD, L Csiba, MD, PhD

(Debrecen, site investigators), L Vecsei, MD, PhD (Szeged, site investigator); Israel A Miller, MD, PhD

(Haifa, site investigator), D Karussis, MD, PhD (Jerusalem, site investigator), J Chapman, MD, PhD (Tel-

Hashomer, site investigator); Italy A Ghezzi, MD (Gallarate, site investigator), G Comi, MD, PhD, V

Martinelli, MD (Milan, site investigators), P Gallo, MD (Padua, site investigator), V Cosi, MD, R

Bergamaschi, MD (Pavia, site investigators), L Durelli, MD, PhD, P Cavalla, MD (Turin, site investigator);

Netherlands CH Polman , MD (Amsterdam, steering committee, eligibility review committee), F Barkhof,MD (Amsterdam, eligibility review committee, central MRI analysis), B Uitdehaag, MD Amsterdam,eligibility review committee), B Anten, MD, R Hupperts, MD (Sittard, site investigators), L Visser, MD (Tilburg, site investigator); Norway K-M Myhr, MD (Bergen, site investigator); Poland A Szczudlik, MD,

PhD (Krakow, site investigator), K Selmaj, MD, PhD (Lodz, site investigator), Z Stelmasiak, MD, PhD, H

Barosik-Psujek, MD (Lublin, site investigators), R Podemski, MD, PhD (Wroclaw, site investigator), Z

Maciejek, MD, PhD, S Wawrzyniak, MD (Bydgoszcz, site investigators); Portugal L Cunha, MD, PhD

(Coimbra, site investigator); Slovenia S Sega-Jazbec, MD (Ljubljana, site investigator); Spain X Montalbán, MD, (Barcelona, steering committee)T Arbizu, MD A SaizHinarejos, MD (Barcelona, siteinvestigators), J Barcena, MD (Barakaldo, site investigator), S MartínezYélamos, MD (Hospitalet de Llobregat, site investigators), R Arroyo, MD (Madrid, site investigator), O Fernandez, MD, PhD (Malaga,site investigator), G IzquierdoAyuso, MD (Seville, site investigator), B Casanova i Estruch, MD (Valencia,site investigator); Sweden J Lycke, MD (Göteborg, site investigator); Switzerland L Kappos, MD (Basel,steering committee, CDMS confirmation committee), A de Vera, MD; S Wu, MD (Basel, CDMSconfirmation committee), E-W Radue (Basel, central MRI analysis), J Kuhle, MD, (Basel, siteinvestigators), H Mattle, MD, PhD(Bern, site investigators), K Beer, MD (St. Gallen, site investigator); United Kingdom R Coleman, MD (Aberdeen, site investigator), DH Miller, MD, PhD (London, steeringcommittee), J Chataway, MD, PhD (London, site investigator), J O'Riordan, MD (Dundee, siteinvestigator), S Howell, MD (Sheffield, site investigator).

Independent advisory board: HF McFarland, MD; J Kesselring, MD; AJ Petkau, PhD; KV Toyka, MD.